← Back to Screener
A

ABBV — AbbVie Inc

AbbVie Inc
ImmunologyScore: 51/100156 Active SignalsFull Profile
C
51

What is the current ABBV catalyst setup?

ABBV is tracked by BiotechSign with a current catalyst score of 51/100 and grade C. The page summarizes 156 active signals, including 0 PDUFA, 0 insider buying, and 1 clinical trial signals, with data refreshed on 2026-07-18.

Company SnapshotUpdated 2026-07-18

As of 2026-07-18, AbbVie Inc (ABBV) has a BiotechSign Catalyst Score of 51/100, rated C. The company has 156 active signals tracked by BiotechSign and 1 clinical trial signal. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.

This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).

Analyst Summary
Verified 2026-04-11

AbbVie Inc (ABBV) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov[5], including 59 Phase 3[1], 48 Phase 2[2], 54 Phase 1[3], 6 Phase 4[4].

Trial NCT07032597[6] evaluates HArmonyCa Lidocaine Injectable Gel in Mid Face Volume Deficit with a target enrollment of 252 participants. Trial NCT06417775[7] evaluates Ubrogepant in Migraine with a target enrollment of 496 participants. Trial NCT04524611[8] evaluates Risankizumab in Crohn's Disease (CD) with a target enrollment of 527 participants.

ABBV has 3 Form 4 insider filings recorded at the SEC in the past 30 days[9].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. ClinicalTrials.gov (2026-04-11)
  5. ClinicalTrials.gov (2026-04-11)
  6. ClinicalTrials.gov · NCT07032597 (2025-08-14)
  7. ClinicalTrials.gov · NCT06417775 (2025-11-12)
  8. ClinicalTrials.gov · NCT04524611 (2026-04-07)
  9. SEC EDGAR · 0001551152 (2026-04-11)
Not financial advice. BiotechSign scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.
CONGRESS TRADESBULLISH
2 buys · 1 sell · 8 total · latest 2025-12-18
CONGRESS TRADESBULLISH
2 buys · 1 sell · 8 total · latest 2025-12-18
CONGRESS TRADESBULLISH
2 buys · 1 sell · 8 total · latest 2025-12-18
CONVERGENCENeutral
4 bullish2 bearish
51
CONVERGENCENeutral
4 bullish2 bearish
51
CONVERGENCENeutral
4 bullish2 bearish
51
FUND FLOW (13F)Distributing
Increased
21
Decreased
20
Exited
6
Top Buyer
Capital World
↗ full detail in StonkWhisper tab
FUND FLOW (13F)Distributing
Increased
21
Decreased
20
Exited
6
Top Buyer
Capital World
↗ full detail in StonkWhisper tab
FUND FLOW (13F)Distributing
Increased
21
Decreased
20
Exited
6
Top Buyer
Capital World
↗ full detail in StonkWhisper tab
DARK POOL
28.7% DP volume · +48.3% WoW
50
DARK POOL
28.7% DP volume · +48.3% WoW
50
DARK POOL
28.7% DP volume · +48.3% WoW
50
PUBLICATION13010 papers
Click to browse recent papers
100
Signal Summary
PDUFA0
Insider0
Clinical1
Data Sources
Dilution◌ LOADING
Sentiment◌ LOADING
SEC EDGAR● LIVE
ClinicalTrials● LIVE
Yahoo Finance● LIVE